NEW YORK (TheStreet) -- Stay here all day for live coverage from the second and final day of the BIO CEO & Investor Conference. The two-day conference, put on by BIO, the biotech industry's main lobbying group, typically spotlights small-cap biotech companies that are often shut out of investor conferences run by large investment banks. Pfizer's(PFE) Dr. Mikael Dolsten, Head of Worldwide Research, kicks off the BIO conference this morning with a breakfast "fireside chat" at 8 am ET. Around the same time, Idenix Pharmaceuticals(IDIX), CEO Ron Renaud will be speaking on CNBC. Given that he's pre-booked for the network likely means he won't be announcing the takeout deal investors have been pining for, but his comments on future plans for his company's hepatitis C drugs will be closely followed. Renaud presents at the BIO conference later this morning. Other noteworthy presenting companies Tuesday include Delcath Systems(DCTH), Keryx Pharmaceuticals(KERX), Oncothyreon(ONTY), Acorda Therapeutics(ACOR) and Human Genome Sciences(HGSI). Gilead Sciences'(GILD) President John Milligan will also be featured in a "fireside chat" this afternoon. I have one-on-one meetings today with Acorda, BioMarin Pharmaceuticals(BMRN) and Affymax(AFFY) To make it easier to follow the news, debate and conversations expected to flow from this years BIO CEO confab, feel free to check in periodically to this live blog that will aggregate all tweets using the #BIOCEO2012 hashtag. An archive of tweets and comments from Day One of the BIO CEO conference is still available. --Written by Adam Feuerstein in Boston. >To contact the writer of this article, click here: Adam Feuerstein. >To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein. >To submit a news tip, send an email to: tips@thestreet.com. Follow TheStreet on Twitter and become a fan on Facebook.
TheStreet Premium Services
Jim Cramer's Action Alerts PLUS:
Trade right alongside a Wall Street pro — enjoy access to his Charitable Trust portfolio and be sent trade alerts BEFORE he makes a move. Learn More
OptionsProfits:
Get 50+ trade ideas a week from the industry's top options experts. Plus — exclusive commentary on market trends and essential trading tools. Learn More
Real Money:
Our team of professional Wall Street Pros — including Jim Cramer, Doug Kass, and Nicholas Vardy — delivers intelligent analysis, timely trade ideas, and colorful commentary. Learn More
Stocks Under $10:
Break into the market with small- and mid-cap stocks... all $10 or less! David Peltier tells you exactly which low-priced stocks he's buying and selling. Learn MoreTo begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
blog comments powered by Disqus
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note |
|
|---|---|---|---|---|
| 12,218.62 | 1,291.60 | 2,778.62 | 15.02 |
Oil *
99.52
|
|
DOWN
174.83 |
DOWN
18.73 |
DOWN
48.72 |
DOWN
0.79 |
10 Yr
1.50%
SPDR Gold
155.50
|
|
-1.41%
|
-1.43%
|
-1.72%
|
-5.00%
|
Data delayed 20 minutes |
Connect with TheStreet